Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction

• Main Authors: Asami Sukeishi (Author), Kotaro Itohara (Author), Atsushi Yonezawa (Author), Yuki Sato (Author), Katsuyuki Matsumura (Author), Yoshiki Katada (Author), Takayuki Nakagawa (Author), Satoshi Hamada (Author), Naoya Tanabe (Author), Eishi Imoto (Author), Shinichi Kai (Author), Toyohiro Hirai (Author), Motoko Yanagita (Author), Shigeru Ohtsuru (Author), Tomohiro Terada (Author), Isao Ito (Author)
• Format: Book
• Published: Wiley, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Remdesivir, a prodrug of the nucleoside analog GS‐441524, plays a key role in the treatment of coronavirus disease 2019 (COVID‐19). However, owing to limited information on clinical trials and inexperienced clinical use, there is a lack of pharmacokinetic (PK) data in patients with COVID‐19...